title: Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells.
abstract: Transforming growth factor-beta (TGF-beta) inducible early gene 1 (TIEG1) is known to induce apoptosis in TGF-beta sensitive pancreatic cancer cells, yet its effect on TGF-beta resistant cancer cells remains unclear. In this study, TIEG1 was found to induce apoptosis in TGF-beta resistant cancer cells and concurrently enhanced gemcitabine chemosensitivity. Down-regulation of stathmin was noted to associate with TIEG1 expression, whilst ectopic overexpression of stathmin prevented TIEG1 mediated growth inhibition of tumor cells. Small interfering RNAs targeting stathmin inhibited pancreatic cancer cell growth. These suggest that stathmin is a downstream target of TIEG1.
authors.affiliation: Institute of Cell Biology, Zhejiang University, Hangzhou, 310058, Zhejiang Province, People's Republic of China.
authors.forename: Lei
authors.initials: L
authors.lastname: Jiang
authors.forename: Yangchao
authors.initials: Y
authors.lastname: Chen
authors.forename: Chu-yan
authors.initials: CY
authors.lastname: Chan
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.forename: Lin
authors.initials: L
authors.lastname: Lin
authors.forename: Ming-liang
authors.initials: ML
authors.lastname: He
authors.forename: Marie C M
authors.initials: MC
authors.lastname: Lin
authors.forename: David T
authors.initials: DT
authors.lastname: Yew
authors.forename: Joseph J Y
authors.initials: JJ
authors.lastname: Sung
authors.forename: Ji-Cheng
authors.initials: JC
authors.lastname: Li
authors.forename: Hsiang-fu
authors.initials: HF
authors.lastname: Kung
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D015536:Down-Regulation; D019008:Drug Resistance, Neoplasm; D051765:Early Growth Response Transcription Factors / Q000502:physiology*; D006801:Humans; D051741:Kruppel-Like Transcription Factors / Q000502:physiology*; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors; D050777:Stathmin / Q000378:metabolism*; D016212:Transforming Growth Factor beta / Q000378:metabolism; D014407:Tumor Cells, Cultured; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D051765:Early Growth Response Transcription Factors; C098111:KLF10 protein, human; D051741:Kruppel-Like Transcription Factors; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D050777:Stathmin; D016212:Transforming Growth Factor beta; D003841:Deoxycytidine; D012264:Ribonucleotide Reductases; D000093542:Gemcitabine